Opinion|Videos|January 8, 2025
Tailoring Treatment Approaches for Fit vs Unfit CLL Patients
A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does your treatment approach differ for IGHV-mutated vs unmutated CLL?
Advertisement
Related to this article
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Arcotatug Tavatecan Improves Survival in CLDN18.2+ Advanced Gastric or GEJ Adenocarcinoma
3
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
4
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
5